Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?Zacks Investment Research • 12/07/23
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023GlobeNewsWire • 11/13/23
Esperion: Navigating The 'Bemp' Of Success Amidst Market Waves And Legal TidesSeeking Alpha • 11/13/23
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023GlobeNewsWire • 11/11/23
Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report?Zacks Investment Research • 08/31/23
Esperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone LitigationSeeking Alpha • 08/29/23
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 08/28/23
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023GlobeNewsWire • 08/26/23
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023GlobeNewsWire • 08/11/23
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023GlobeNewsWire • 07/07/23
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) TabletGlobeNewsWire • 06/28/23
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific SessionsGlobeNewsWire • 06/24/23